{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Graft+Function%2FSurvival",
    "query": {
      "condition": "Graft Function/Survival"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T16:05:24.376Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00885820",
      "title": "Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "MMF",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids (Prednisone)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2001-09",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2014-09-18",
      "last_synced_at": "2026-07-22T16:05:24.376Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00885820"
    },
    {
      "nct_id": "NCT04226859",
      "title": "Trajectories of Glomerular Filtration Rate and Progression to End Stage Renal Disease After Kidney Transplantation",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Transplant Failure",
        "Kidney Function Issue"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Paris Translational Research Center for Organ Transplantation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14000,
      "start_date": "2000-01",
      "completion_date": "2020-06",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-07-22T16:05:24.376Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04226859"
    },
    {
      "nct_id": "NCT04258891",
      "title": "Multidimensional System to Dynamically Predict Graft Survival After Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Transplant Failure"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Paris Translational Research Center for Organ Transplantation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14000,
      "start_date": "2004-01-01",
      "completion_date": "2020-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-07-22T16:05:24.376Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04258891"
    },
    {
      "nct_id": "NCT00307125",
      "title": "Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant",
        "Kidney Transplant Recipient",
        "Graft Function/Survival",
        "de Novo HLA Antibodies Development"
      ],
      "interventions": [
        {
          "name": "Rituximab plus immunosuppression",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus immunosuppression",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "5 Years to 70 Years"
      },
      "enrollment_count": 757,
      "start_date": "2006-03",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2015-03-23",
      "last_synced_at": "2026-07-22T16:05:24.376Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00307125"
    },
    {
      "nct_id": "NCT00931255",
      "title": "Tacrolimus to Sirolimus Conversion for Delayed Graft Function",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplant",
        "Delayed Graft Function"
      ],
      "interventions": [
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 32,
      "start_date": "2009-04",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-07-22T16:05:24.376Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00931255"
    },
    {
      "nct_id": "NCT01817959",
      "title": "Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Islet Transplantation in Diabetes Mellitus Type 1"
      ],
      "interventions": [
        {
          "name": "Reparixin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 51,
      "start_date": "2012-10",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2024-01-03",
      "last_synced_at": "2026-07-22T16:05:24.376Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01817959"
    },
    {
      "nct_id": "NCT00248040",
      "title": "Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemia-Reperfusion Injury",
        "Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Reparixin continuous infusion",
          "type": "DRUG"
        },
        {
          "name": "reparixin intermittent infusion",
          "type": "DRUG"
        },
        {
          "name": "placebo infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2005-10",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2024-01-10",
      "last_synced_at": "2026-07-22T16:05:24.376Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00248040"
    },
    {
      "nct_id": "NCT07269041",
      "title": "Immune Tolerance Induction After Liver Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Liver Transplantation",
        "Immune Tolerance",
        "Immune Tolerance/Drug Effects",
        "Graft Survival",
        "Hematopoietic Stem Cell",
        "Chimerism",
        "Immunosuppression After Liver Transplantation",
        "Immunosuppression Disorders",
        "End Stage Liver Disease"
      ],
      "interventions": [
        {
          "name": "Donor Hematopoietic Stem and Progenitor Cell Infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2026-02-20",
      "completion_date": "2033-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-07-22T16:05:24.376Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07269041"
    }
  ]
}